278: Illumina, Grail and FTC scrutiny of vertical mergers in human genetic technologies

Rashid AI et al., The American Journal of Human Genetics, Corrected proof. doi:10.1016/j.ajhg.2025.12.012 - US antitrust shifts in human genetic technologies: FTC scrutiny of Illumina’s acquisition of Grail alters NGS market oversight and could affect spin-offs and startups. Key terms: Illumina, Grail, vertical mergers, FTC merger guidelines, non-compete rule.

Study Highlights:
This perspective examines the US legal and regulatory landscape for human genetic and genomic technologies, focusing on FTC and DOJ policy changes and enforcement habits. Using a case-study approach centered on Illumina’s proposed acquisition and eventual divestiture of Grail, the authors review updated merger guidelines, non-compete rule developments, and exclusive-dealing concerns. They report that the 2023 merger guidelines lowered thresholds for presumed anti-competitiveness and that the FTC’s challenge emphasized risks to nascent mult-cancer early detection competitors that rely on next-generation sequencing platforms. The authors conclude that heightened vertical-merger scrutiny may reduce spin-offs and early-stage acquisitions, prompting firms to favor in-house R&D or alternate collaboration models.

Conclusion:
Heightened scrutiny of vertical mergers and attention to nascent competition in US antitrust policy is likely to reshape biotechnology strategies by reducing spin-offs and encouraging in-house development.

Music:
Enjoy the music based on this article at the end of the episode.

Article title:
Competition in human genetic technologies: The current US legal landscape

First author:
Rashid AI

Journal:
The American Journal of Human Genetics, Corrected proof. doi:10.1016/j.ajhg.2025.12.012

DOI:
10.1016/j.ajhg.2025.12.012

Reference:
Rashid AI, Rincon NA, Rihani N, Wagner JK. Competition in human genetic technologies: The current US legal landscape. The American Journal of Human Genetics. 2026;113:1–10. https://doi.org/10.1016/j.ajhg.2025.12.012

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) - https://creativecommons.org/licenses/by/4.0/

Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00

Official website https://basebybase.com

On PaperCast Base by Base you’ll discover the latest in genomics, functional genomics, structural genomics, and proteomics.

Episode link: https://basebybase.com/episodes/illumina-grail-vertical-mergers

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-02-02.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited the transcript sections that discuss antitrust policy landscape, the Illumina/Grail vertical merger case, regulatory instruments (HSR, Sherman, Clayton), NASCENT competition, spin-offs and IRS spin-off rules, non-compete status, and startup financing implications.
- transcript topics: Illumina/Grail vertical merger case; Foreclosure theory in vertical mergers; Open offer and divestiture outcome; 2023 merger guidelines and vertical mergers; Nascent competition and spin-offs; IRS rules on corporate spin-offs

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- Illumina/Grail case as a vertical merger example with divestiture
- Foreclosure as a potential anti-competitive mechanism in vertical mergers
- 2023 merger guidelines lowered thresholds for presumed anti-competitiveness
- IRS spin-off rules tightened in January 2025 with stricter proof and reporting
- Non-compete regulation status: initial nationwide ban with subsequent rulings and continued case-by-case enforcement
- Startup financing pressures (kill zone) due to antitrust scrutiny and exit constraints

QC result: Pass.